Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Conservative Treatment With Relative Motion Flexion Orthosis for Boutonniere Injuries in Fingers

2 de novembro de 2026 atualizado por: Lund University Hospital

Conservative Treatment With Relative Motion Flexion (RMF) Orthosis for Boutonniere Injuries

Boutonnière injuries involve damage to the central slip of the extensor tendon over the proximal interphalangeal (PIP) joint (zone III) of the finger. These injuries disrupt the balance of the extensor mechanism, leading to volar displacement of the lateral bands and progressive development of Boutonnière deformity, characterized by PIP joint flexion and distal interphalangeal (DIP) joint hyperextension. Due to the gradual onset and closed nature of the injury, diagnosis is often delayed, and untreated cases may result in joint contractures, reduced range of motion (ROM), pain, and functional limitations.

Treatment is typically conservative and requires prolonged immobilization and splinting, often followed by dynamic orthoses such as Capener splints. However, evidence supporting current treatment strategies is limited and clinical outcomes are variable. Recently, the Relative Motion Flexion (RMF) orthosis has been introduced as an alternative approach aimed at restoring extensor mechanism balance. Existing evidence is limited to small or heterogeneous studies, highlighting the need for further evaluation.

This pilot study aims to assess the feasibility and preliminary effects of RMF orthosis treatment in patients with Boutonnière injuries. The primary objective is to evaluate changes in finger range of motion (ROM) and to estimate variability and within-subject correlations to inform sample size calculations for a future randomized controlled trial. Additional feasibility outcomes include recruitment rate, adherence to treatment, and practicality of measurement procedures.

Secondary objectives include evaluating pain, grip strength, functional hand limitations in daily activities, and patient-reported tolerability and comfort of the orthosis.

The study will be conducted as a prospective longitudinal cohort pilot study with repeated within-subject measurements at baseline, 3 months, and 12 months. A total of 25 adult patients with acute or subacute closed zone III extensor tendon injuries will be recruited consecutively at the Hand Surgery Rehabilitation Unit, Skåne University Hospital, Malmö.

Inclusion criteria include age ≥18 years, positive pencil test, and confirmed central slip injury. Exclusion criteria include open injuries, significant joint contractures (>20°), chronic injuries (>1 year), previous surgery or trauma in the same finger, concomitant fractures or tendon/nerve injuries, inflammatory arthropathies, and severe cognitive or psychiatric conditions or substance abuse.

All participants will receive treatment with an RMF orthosis according to a structured protocol consisting of 6 weeks of continuous use followed by 6 weeks of intermittent daytime and nighttime use. No separate control group will be included; analyses will be based on within-subject comparisons over time.

Primary outcome is ROM measured at the MCP, PIP, and DIP joints using a goniometer. Secondary outcomes include pain (Numeric Rating Scale), grip strength (Jamar dynamometer), hand function (QuickDASH), adherence and tolerability questionnaires, and recruitment rate.

Data will be analyzed using descriptive statistics and nonparametric longitudinal methods, including Friedman tests and Wilcoxon signed-rank tests for paired comparisons across time points.

The study will be conducted in accordance with the Declaration of Helsinki, with ethical approval sought from the Swedish Ethical Review Authority. All participants will provide informed consent, and data will be pseudonymized in accordance with GDPR. The study poses minimal risk, and participants will be monitored throughout treatment with adjustments made as needed.

This pilot study will generate essential data on treatment variability, feasibility, and preliminary outcomes of RMF orthosis use. The results will inform the design of a future randomized controlled trial and may contribute to improved evidence-based management of Boutonnière injuries, potentially leading to better functional outcomes and more efficient rehabilitation strategies.

Visão geral do estudo

Descrição detalhada

Boutonnière injuries involve disruption of the central slip of the extensor tendon over the proximal interphalangeal (PIP) joint (zone III) of the finger. This leads to imbalance in the extensor mechanism, with volar displacement of the lateral bands and progressive development of Boutonnière deformity, characterized by PIP flexion and compensatory DIP hyperextension. Due to the often gradual onset and closed injury mechanism, diagnosis is frequently delayed. If untreated, the condition may result in stiffness, joint contractures, pain, reduced range of motion (ROM), and long-term functional impairment.

Current conservative treatment typically consists of prolonged immobilization of the PIP joint in extension, followed by dynamic orthotic management. Although widely used, evidence supporting existing treatment strategies is limited and outcomes are variable. Treatment is often demanding for patients due to prolonged splinting and restricted hand function during rehabilitation.

The Relative Motion Flexion (RMF) orthosis has been introduced as an alternative treatment strategy aimed at restoring balance within the extensor mechanism while allowing greater functional use of the hand during rehabilitation. However, current evidence is limited to small case series, heterogeneous cohorts, and studies with methodological limitations. Further prospective evaluation is therefore needed.

This study is designed as a prospective longitudinal pilot cohort study with repeated within-subject measurements. The primary purpose is to evaluate feasibility and to generate parameters required for planning a future randomized controlled trial, including estimates of variability in range of motion outcomes and within-subject correlations over time.

The study will also explore preliminary effects of RMF orthosis treatment on finger range of motion, as well as secondary outcomes including pain, grip strength, functional hand limitations, and patient-reported tolerability and adherence.

A total of 25 adult patients with acute or subacute closed central slip injuries (zone III) will be recruited consecutively at the Hand Surgery Rehabilitation Unit, Skåne University Hospital, Malmö, Sweden.

Participants will be treated with an RMF orthosis according to a structured rehabilitation protocol consisting of 6 weeks of continuous use followed by 6 weeks of intermittent use during daytime and nighttime. Treatment is delivered as part of routine rehabilitation follow-up, with adjustments made as clinically indicated.

Outcomes will be assessed at baseline, 3 months, and 12 months after treatment initiation. Primary outcome is range of motion (ROM) measured at the MCP, PIP, and DIP joints using a goniometer. Secondary outcomes include pain intensity (Numeric Rating Scale), grip strength (Jamar dynamometer), hand function (QuickDASH), and a study-specific questionnaire assessing adherence and tolerability. Recruitment rate will be recorded as number of eligible patients included per month.

As a pilot study, no control group is included. Analyses will focus on within-subject changes over time and estimation of parameters needed for sample size calculation in a future randomized controlled trial. Data will be analyzed using descriptive statistics and nonparametric longitudinal methods, including Friedman tests and Wilcoxon signed-rank tests for paired comparisons across time points.

The study will be conducted in accordance with the Declaration of Helsinki. Ethical approval will be sought from the Swedish Ethical Review Authority (Etikprövningsmyndigheten). Written informed consent will be obtained from all participants. All data will be pseudonymized and handled in accordance with applicable data protection regulations (GDPR). The study involves minimal risk, and participants will be monitored throughout the rehabilitation period.

This pilot study will provide essential feasibility data and preliminary clinical outcomes for RMF orthosis treatment. The results will inform the design of a future randomized controlled trial and may contribute to improved evidence-based management of Boutonnière injuries, with the potential to enhance functional recovery and optimize rehabilitation strategies.

Tipo de estudo

Intervencional

Inscrição (Estimado)

25

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

  • Nome: Elisabeth Brogren, PhD
  • Número de telefone: +46 40 331185

Locais de estudo

    • Skåne County
      • Malmö, Skåne County, Suécia, 205 02
        • Recrutamento
        • Skåne University Hospital (Hand Surgery Rehabilitation Unit)
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • persons with acute and subacute closed injurt to the central slip/extensor tendon zon 3
  • positive pencil test

Exclusion Criteria:

  • open injury or infection
  • joint contracture >20
  • trauma >1 year ago
  • previous trauma or surgery in the same finger
  • simultaneous crush injury
  • concomitant fracture and/or digital nerve injury and/or flexor tendon injury
  • rheumatoid arthritis
  • drug abuse, sever cognitive impairment, or severe psychological disorder

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Relative Motion Flexion (RMF) orthosis intervention group

Participants in this arm receive treatment with a Relative Motion Flexion (RMF) orthosis as part of a structured rehabilitation protocol. The intervention consists of 6 weeks of continuous orthosis use followed by 6 weeks of intermittent use during daytime and nighttime. No control intervention is used, and outcomes are assessed longitudinally within the same participants over time.

The intervention consists of treatment with a Relative Motion Flexion (RMF) orthosis for patients with Boutonnière injuries of the finger (zone III extensor tendon injuries). The orthosis is applied according to a structured rehabilitation protocol consisting of 6 weeks of continuous wear, followed by 6 weeks of intermittent use during daytime and nighttime. The aim of the intervention is to restore extensor mechanism balance while allowing functional use of the hand during rehabilitation. Participants receive standard follow-up at the hand surgery rehabilitation unit, with adjustments made as clinically indicated.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Range Of Motion (ROM)
Prazo: baseline, 3 months, 12 months

Range of Motion in each joint MCP, PIP, DIP

baseline, 3 months, 12 months
Range of motion (ROM)
Prazo: baseline, 3 months, 12 months

Active range of motion assessed with a finger goniometer

baseline, 3 months, 12 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

30 de junho de 2026

Conclusão Primária (Estimado)

31 de dezembro de 2027

Conclusão do estudo (Estimado)

31 de dezembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

2 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

2 de novembro de 2026

Primeira postagem (Real)

6 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

6 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

2 de novembro de 2026

Última verificação

1 de junho de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • no grant number assigned
  • Region Skåne FoU funding (Outro identificador: no grant number assigned)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Descrição do plano IPD

IPD will not be publicly shared. De-identified data may be available upon reasonable request and ethical approval.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever